The Effect of Topical Application of Royal Jelly on Chemoradiotherapy-Induced Mucositis in Head and Neck Cancer: A Preliminary Study

Abstract EN

Purpose.

One of the common side effects experienced by head and neck cancer patients on chemoradiotherapy is mucositis.

Severe mucositis may be controllable by limiting cancer therapy, but it has resulted in decreasing the completion rate of chemoradiotherapy.

The efficacy of royal jelly (RJ) as prophylaxis against chemoradiotherapy-induced mucositis was evaluated through clinical scoring of oral and pharyngeal mucositis.

Methods.

In this randomized, single-blind (physician-blind), clinical trial, 13 patients with head and neck cancer requiring chemoradiation were randomly assigned to two groups.

Seven patients assigned to the study group received RJ, and 6 patients were assigned to the control group.

RJ group patients took RJ three times per day during treatment.

The patients in both groups were evaluated twice a week for the development of mucositis using Common Terminology Criteria for Adverse Events version 3.0.

Results.

A significant reduction in mucositis was seen among RJ-treated patients compared with controls ( P < 0.001 ).

Conclusion.

This study demonstrated that prophylactic use of RJ was effective in reducing mucositis induced by chemoradiotherapy in head and neck cancer patients.

However, further studies are needed because of the small sample size and the absence of double blinding.